about
sameAs
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveFundament and Prerequisites for the Application of an Antifungal TDM ServiceAntifungal prophylaxis in pediatric hematology/oncology: new choices & new data.Voriconazole pharmacokinetics and pharmacodynamics in children.Voriconazole pharmacokinetics in liver transplant recipients.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, andSerum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapyEvaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infectionsClinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Human tissue distribution of voriconazole.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Inflammation is associated with voriconazole trough concentrations.Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapyObservational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.Achieving target voriconazole concentrations more accurately in children and adolescents.Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tabletsPulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicityTrough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patientsPharmacokinetics of antifungal agents in children.Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.A review of clinical experience with newer antifungals in childrenPenicillium marneffei chylous ascites in acquired immune deficiency syndrome: a case report.Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosisTriazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazoleTherapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Bench-to-bedside review: Candida infections in the intensive care unit.Antimicrobial-associated QT interval prolongation: pointes of interest.Software for dosage individualization of voriconazole for immunocompromised patientsPlasma Voriconazole Estimation by HPLC.
P2860
Q26771180-02C72F45-EEAC-4429-86D7-5244124859D2Q27009221-9693E917-D399-4E5C-8A79-DC31AD47CD65Q28085352-F5ABFE92-FC51-4C55-B53C-B5EFEF73460AQ33559503-FE8E95DB-B9C2-44A7-8DF0-B63651842517Q33577291-30665A5F-66BE-4618-9ED0-1395BB67D08CQ33613685-71EA4CA1-9E12-4721-97E3-20DD534258D2Q33849298-BEE7E7CB-CD85-4E21-8D08-D964CB6CF671Q34138276-549276BB-481C-4643-B5E2-78B7EA43C7AEQ34150943-E5B69607-35C7-4C38-BABC-141319582069Q34233142-AD600446-9372-4724-8E87-E33E4F648E01Q34309603-60A4E825-FCE3-4466-8891-52EB555F524DQ34413393-91A67901-B7ED-4EB2-A620-68900E38FEF2Q34483712-0E9E1140-7B5D-4911-8DF4-C776792618AFQ34505582-988F82D4-59C5-4745-A612-D371ECFA2B3CQ34529318-1C327C0A-F61D-4B43-82BA-B9DD0576044AQ34532546-8962A304-300B-4021-93A6-AC620CA55C9DQ34597394-A76DBD39-D657-4B44-9E30-DB5A1F942FD2Q34641443-3F2947C3-DE80-45EA-B5C5-4E5A96EA383DQ35114591-B9B90E18-F5D4-40E2-8243-A9D5C4DC304FQ35270270-F2699162-B7BF-4D43-98A8-FA9C6AFC3199Q35598464-75991461-14C7-419C-937C-04DFFD4F8BBEQ35598532-25ED9528-E6C9-4BD0-A34E-403E876D729DQ35607652-15B42C9D-DA07-457B-ADE0-BFF503692E4EQ35635830-EFDEC35A-6183-46A1-BD37-8698AE773025Q35647746-5D4A29C3-18DA-4FFC-B291-F6BBA09BDB94Q35889014-D6D26506-A91A-4B09-B64E-9ADF6D7CC963Q35941502-DAC38CDA-73F7-4436-99C6-1AB6DA4625E3Q35954530-12451F71-F2F8-496F-AF5E-F7BDDFCB9A9BQ36087577-65B76F35-4E0F-4F18-A7C3-B4D669482BCEQ36163345-98CCE0B2-8666-40A3-8A33-261C347105F2Q36172497-19CAA267-74CC-41BF-9400-C26A2887F8D8Q36290698-F31C0C20-374D-49C6-83C4-27D669353ACAQ36310486-B6C4D354-70FE-499C-AB83-71D7D4815BB6Q36505539-A765DEE5-3A58-4970-94B7-00B80074976AQ36521993-21753652-D7B2-433C-9797-214714385F06Q36608562-3BDD848E-A67C-4AB1-B574-4FAF0C6ABAA5Q36641985-15BE7AF4-603E-4CE5-AD4D-7C931C858BC6Q36655034-CFFCA553-4A81-40AA-839F-BD86F32D9A5DQ36757595-EC88FA95-5324-4CB8-A5A9-BEE5F5AB6A8FQ36764126-0EDA871D-C00F-41FF-9196-5C3C4F0737E7
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Voriconazole therapeutic drug monitoring
@nl
Voriconazole therapeutic drug monitoring.
@ast
Voriconazole therapeutic drug monitoring.
@en
type
label
Voriconazole therapeutic drug monitoring
@nl
Voriconazole therapeutic drug monitoring.
@ast
Voriconazole therapeutic drug monitoring.
@en
prefLabel
Voriconazole therapeutic drug monitoring
@nl
Voriconazole therapeutic drug monitoring.
@ast
Voriconazole therapeutic drug monitoring.
@en
P2093
P2860
P1476
Voriconazole therapeutic drug monitoring
@en
P2093
P2860
P304
P356
10.1128/AAC.50.4.1570-1572.2006
P407
P50
P577
2006-04-01T00:00:00Z